Apple has been gaining momentum for its ResearchKit since rolling out the platform earlier this year, with the first batch of studies using the product recording high rates of enrollment for sponsors. The platform's success caught the eye of Yale University scientists, who are planning to use ResearchKit for a study of heart problems in children and adults.
Tiny OTC-traded micro-cap Avita Medical has won backing from the U.S. Biomedical Advanced Research and Development Authority (BARDA) of its PMA approval trial for its ReCell burn treatment device. It will get $16.9 million upfront for the study and for procurement of more than 5,000 of the devices. The ongoing pivotal trial is expected to complete enrollment by the end of the this year.
Royal Philips and the Massachusetts Institute of Technology have teamed up to develop a noninvasive means of measuring intracranial pressure to detect brain injuries. It's expected to incorporate Philips' ultrasound technology and MIT's physiological modeling.
PRA Health Sciences has joined forces with a trial site group to focus on vaccine development, hoping to speed up patient recruitment and get more clinical studies rolling.
CRO Chiltern, in the process of integrating its latest acquisition, is focusing in on endocrinology and metabolism, broadening its expertise with an eye on diabetes R&D.
Third Rock entrepreneurs Cary Pfeffer and Robert Tepper are taking top interim posts at the newly unveiled Neon Therapeutics, spearheading an immuno-oncology R&D effort after snagging an early-stage therapy fostered at the prestigious Broad Institute and Dana-Farber. And they have a $55 million bankroll from Third Rock, Clal Biotechnology Industries and Access Industries to set up the company.
Less than a month after pairing with the NIAID on a Phase II trial of its universal flu vaccine in the U.S., BiondVax is looking to Hungary for its next trial, this time in conjunction with an overseas public health authority.
InnFocus has nabbed a pair of strategic ophthalmic investors in its Series C financing for $32.8 million. The cash infusion will go to the final phase of clinical testing for the startup's MicroShunt, which is expected to be a minimally invasive alternative to surgery for primary open angle glaucoma.
Royal Philips has grand plans for growth in Israel. CEO Frans Van Houten opened up to Israeli newspaper Globes about the company's med tech ambitions in the country, months after Philips kicked off operations for a new technology incubator in Israel with partner Teva Pharmaceutical Industries.
Following up on data from a Phase I study in canines with osteosarcoma, Advaxis is taking its HER2 cancer vaccine into human trials.